Methylprednisolone is a potent synthetic glucocorticoid, approximately 5 times more potent than hydrocortisone. The 80mg strength is a high-dose formulation primarily used for acute, severe inflammatory and autoimmune conditions, as well as for pulse therapy in critical care and rheumatology settings. It exerts profound anti-inflammatory, immunosuppressive, anti-allergic, and anti-proliferative effects.
Adult: Dose varies widely by indication. For severe conditions: 40-80 mg IV/IM/orally once daily or in divided doses. For MS exacerbation: 500-1000 mg IV daily for 3-5 days (pulse). For cerebral edema: Initial loading dose of 80-120 mg IV, followed by 20-80 mg IV/orally daily. MUST BE TAPERED.
Note: Oral: Take with food or milk to minimize GI upset. Do not crush or chew enteric-coated tablets. IV: Methylprednisolone sodium succinate (Solumedrol) is reconstituted and given as a slow IV push over several minutes or as an IV infusion. IM: Deep intramuscular injection into gluteal muscle. Timing: For daily dosing, administer in the morning to mimic circadian rhythm and reduce HPA axis suppression.
Methylprednisolone is a potent agonist of the cytosolic glucocorticoid receptor (GR). The drug-receptor complex translocates to the nucleus, where it binds to glucocorticoid response elements (GREs) in DNA, leading to up-regulation (transactivation) of anti-inflammatory proteins like lipocortin-1, and down-regulation (transrepression) of genes encoding pro-inflammatory cytokines (IL-1, IL-2, IL-6, TNF-α), chemokines, adhesion molecules, and enzymes like COX-2. It also induces apoptosis of lymphocytes, particularly T-cells and eosinophils.
Pregnancy: Pregnancy Category C (US FDA). May cross placenta. Use only if potential benefit justifies potential fetal risk. Chronic use in pregnancy associated with fetal adrenal suppression, low birth weight, and cleft palate (first trimester). Inhaled forms preferred for chronic conditions. For severe maternal illness (e.g., SLE flare), benefits may outweigh risks.
Driving: May cause dizziness, vertigo, or visual disturbances. Patients should not drive or operate machinery until they know how the drug affects them.
| Warfarin/Anticoagulants | Methylprednisolone may alter anticoagulant response (increase or decrease); monitor INR closely. | Major |
| Antidiabetics (Insulin, Metformin, Sulfonylureas) | Corticosteroids cause hyperglycemia; may require increased antidiabetic dose. | Major |
| NSAIDs (Ibuprofen, Diclofenac) | Increased risk of GI ulceration and bleeding. | Major |
| Diuretics (Furosemide, Thiazides) | Enhanced potassium loss leading to severe hypokalemia. | Major |
| CYP3A4 Inducers (Phenytoin, Phenobarbital, Rifampicin) | Increased metabolism of methylprednisolone, reducing its efficacy. | Moderate |
| CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin) | Decreased metabolism of methylprednisolone, increasing toxicity risk. | Moderate |
| Live Vaccines (MMR, Varicella, OPV) | Risk of disseminated vaccine-induced infection; avoid. | Major |
| Digoxin | Hypokalemia potentiates digoxin toxicity. | Moderate |
Same composition (Methylprednisolone (80mg)), different brands: